CN101850039A - Composition with auxiliary lipid-lowering function - Google Patents
Composition with auxiliary lipid-lowering function Download PDFInfo
- Publication number
- CN101850039A CN101850039A CN200910236322A CN200910236322A CN101850039A CN 101850039 A CN101850039 A CN 101850039A CN 200910236322 A CN200910236322 A CN 200910236322A CN 200910236322 A CN200910236322 A CN 200910236322A CN 101850039 A CN101850039 A CN 101850039A
- Authority
- CN
- China
- Prior art keywords
- extract
- test
- compositions
- parts
- polygoni multiflori
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a composition with an auxiliary lipid-lowering function, which is prepared mainly with the following materials in parts by weight: 4.5-13.5 of folium ginkgo extract, 5.5-16.5 parts of red yeast, 5-15 parts of prepared radix polygoni multiflori extract and 5-15 parts of rhizoma alisma extract. Since the folium ginkgo extract, the red yeast, the prepared radix polygoni multiflori extract and the rhizoma alisma extract are used as the main raw materials, the prepared composition and derivatives thereof have the auxiliary lipid-lowering function. The raw materials selected in the invention are medical and edible raw materials, and the formula is safe and effective.
Description
Technical field
The present invention relates to a kind of compositions with auxiliary lipid-lowering function.
Background technology
One group of disease that hyperlipemia increases for blood plasma lipide concentration, major lesions are that atherosclerosis and thrombosis take place, and are the commonly encountered diseases of serious harm health of people, and especially the middle-aged and elderly people of commute period of disease is very harmful.To asymptomatic atherosclerosis, stricture of artery, needing to arrive in year surplus in the of ten the time of more than two decades from normal tremulous pulse, is a very very long process.And need only short a few minutes to causing cardiovascular and cerebrovascular disease (as heart disease or apoplexy) from asymptomatic atherosclerosis.Therefore prevent cordis and cerebral accident promptly to prevent more to overweight treatment from early setting about.
Raising along with living standards of the people, obvious variation has taken place in dietary structure, the intake of saturated fat and cholesterol increases, and the intake of carbohydrate reduces just gradually, changed the dietary structure that is unfavorable for the healthy high fat that is enough to cause dyslipidemia, hypercholesterolemia, low-carb into by helping healthy dietary structure originally, add bad life style such as lack motion, smoking, drink, the hyperlipidemia sickness rate increases year by year, and age of onset has the trend of rejuvenation gradually.Because of causing cardiovascular and cerebrovascular disease that atherosclerosis causes, hyperlipidemia become serious threat human life's formidable enemy.So, except that the active treatment hyperlipidemia, strengthen daily health caring, active development health food easily and effectively, significant to the sickness rate of preventing and treating arteriosclerosis, reduction cardiovascular and cerebrovascular disease.
At present in the international market, based on statins, and at home, the Statins medicine has only accounted for 40% of blood fat reducing medicine and health food to the treatment of hyperlipidemia.The health food that some are made with Chinese medicine extract or pufa-containing is owing to having remarkable auxiliary antilipemic effect and the safe welcome that is subjected to people with hyperlipidemia.
Summary of the invention
The purpose of this invention is to provide a kind of compositions with auxiliary lipid-lowering function.
For achieving the above object, technical scheme of the present invention provides a kind of compositions with auxiliary lipid-lowering function, is mainly made by the material of following parts by weight: Folium Ginkgo extract: 4.5-13.5 part; Monas cuspurpureus Went: 5.5-16.5 part; Radix Polygoni Multiflori Preparata extract: 5-15 part; Rhizoma Alismatis extract 5-15 part.Folium Ginkgo extract, Monas cuspurpureus Went, Radix Polygoni Multiflori Preparata extract and the Rhizoma Alismatis extract that the present invention adopts is standard extract or commercially available common commodity commonly used.
Above-mentioned compositions is preferably made by the material of following parts by weight: Folium Ginkgo extract: 9 parts; Monas cuspurpureus Went: 11 parts; Radix Polygoni Multiflori Preparata extract: 10 parts; Rhizoma Alismatis extract: 10 parts.
Compositions of the present invention, wherein Folium Ginkgo extract is that Chinese Pharmacopoeia 2005 editions records kind, the extract that it is processed into through conventional extracting method for Folium Ginkgo, for sundown to tan powder; Mildly bitter flavor.Folium Ginkgo extract preferably contains total flavones 〉=5.0 weight % among the present invention.
Compositions of the present invention, wherein Monas cuspurpureus Went is the fungus monascus parpureus Went, commodity Monas cuspurpureus Went commonly used is for adopting the product that obtains after the excellent species fermentation, it contains abundant bioactive enzyme and several physiological active substances, as Monacolin-K (Monacolin K, or claim lovastatin), Monascus anka Nakazawa et sato metabolites such as ergosterol, γ-An Jidingsuan, natural phytohormone, without any side effects, be a kind of natural, safe and effective health food, pharmaceutical raw material.Monas cuspurpureus Went preferably contains lovastatin 〉=0.5 weight % among the present invention.
Compositions of the present invention, wherein Radix Polygoni Multiflori Preparata extract is the process of preparing Chinese medicine processed goods of Radix Polygoni Multiflori.Its a kind of method for making can for: get Radix Polygoni Multiflori pieces or piece, mix thoroughly with decoction of black soybean, put in the appropriate vessel of non iron, stew to juice and exhaust according to the method for stewing; Or according to the steaming method, steamed or mix the back thoroughly with decoction of black soybean and steam, steam to the inside and outside sepia that all is, or shine to half-dried section, drying.Every 100kg Radix Polygoni Multiflori pieces (piece) is used Semen sojae atricolor 10kg.Wherein the decoction of black soybean method for making is for getting Semen sojae atricolor 10kg, and it is an amount of to add water, boils about 4 hours, and the about 15kg of extractive, bean dregs added decocting in water about 3 hours again, the about 10kg of extractive, merge the about 25kg of decoction of black soybean.The Radix Polygoni Multiflori Preparata extract that makes is the piece sheet of irregular shrunk, thick about 1cm.Surface pitchy or sepia, uneven.Matter is hard, section cutin sample, sepia or black.Feeble QI, it is little sweet and pained to distinguish the flavor of.And Radix Polygoni Multiflori Preparata extract preferably contains general anthraquinone 〉=1.0 weight % among the present invention.
Compositions of the present invention, wherein Rhizoma Alismatis extract is the dry tuber extract of Alismataceae plant Rhizoma Alismatis Alisma orientalis (Sam.) Juzep..The Rhizoma Alismatis main product in Fujian, Sichuan, Jiangxi.Tubers sphere, ellipse or oval, long 2-7 centimetre, diameter 2-6 centimetre, there is umbilical stem trace on the top, the tool warty bud trace that the bottom has; Surface yellow-white or fallow has irregular horizontal ring-type shallow ridges stricture of vagina (joint trace), and the diffusing mark of fibrous root that most tiny projections are arranged; Matter is solid, the section yellow-white, and mealiness has most pores; Feeble QI, mildly bitter flavor.It contains multiple tetracyclic triterpene keto-alcohol derivant: alisol (alisol) A-C and acetas, epialisol A (epialisolA), 23-acetylalisol B, C, 24-acetylalisol A; Other contains a small amount of volatile oil, and the master contains sulfoorientalol A-D, alismol, alismoxide (alismoxide) etc.; Rhizoma Alismatis extract preferably contains alisol 〉=0.5 weight % among the present invention.
The various extracts that relate among the present invention be raw material of Chinese medicine through water carry or alcohol extraction after product, they are extensive use on market all, the preparation of various extracts is existing technology, the product that obtains is difference to some extent on material concentration just, and its various products all can practice in the present invention.
In addition, compositions provided by the invention can also contain as adjunct ingredients such as flavoring agent, antioxidants.Flavoring agent can be selected from Mel, sucrose, sweeting agent such as xylitol etc.; Antioxidant can be selected from vitamin C etc.
Further, the invention provides a kind of health food with auxiliary lipid-lowering function, it contains above-mentioned compositions.Remove and contain the combinations thereof beyond the region of objective existence, health food provided by the invention can add some flavoring agents, as fruit essence, sweeting agent etc. in right amount according to the taste hobby of consumer; Also can utilize the adjuvant or the carrier of some food stage, the food of be prepared into various industrialization, easily producing, easily transport and carry, as have the health-caring biscuit etc. of auxiliary lipid-lowering function.
Further, the invention provides a kind of pharmaceutical preparation with auxiliary lipid-lowering function, it contains above-mentioned compositions and pharmaceutically acceptable carrier.It can be acceptable tablet, pill, capsule, granule, electuary, oral liquid or syrup clinically.Be preferably capsule, its every 100g product contains total flavones 1.3g, lovastatin 0.12g.
It is primary raw material that the present invention adopts Folium Ginkgo extract, Monas cuspurpureus Went, Radix Polygoni Multiflori Preparata extract, Rhizoma Alismatis extract, and compositions of making and derived product thereof have the function of auxiliary antilipemic.Wherein Folium Ginkgo sweet in the mouth, hardship, puckery, property is flat, and GUIXIN, lung meridian have astringing the lung, relieving asthma, blood circulation promoting and blood stasis dispelling, analgesic effect; Be used for cough and asthma due to lung deficiency, coronary heart disease and angina pectoris.The Monas cuspurpureus Went sweet in the mouth is flat, and is nontoxic, but blood circulation promoting and blood stasis dispelling, strengthening the spleen to promote digestion; Be used for post partum longtime lochia, stasis is suffered from abdominal pain, food stagnation is full, red white dysentery, traumatic injury, cholesterol reducing and triglyceride.Radix Polygoni Multiflori Preparata sweet in the mouth bitterness, tepor is returned liver, the heart, kidney channel, has invigorating the liver and kidney, benefiting essence-blood, bone and muscle strengthening, the effect of cholesterol reducing.The Rhizoma Alismatis slightly sweet flavor, be slightly cold, return kidney, urinary bladder channel, but promoting diuresis to eliminate damp pathogen, rush down the kidney fire clearly, cholesterol reducing, triglyceride are arranged, increase coronary flow, lipotropic effect.Each raw material all has the function of definite auxiliary antilipemic through modern pharmacology experiment and clinical practice proof.Basic Theories of Chinese Medicine thinks that the pathogenesis of " hyperlipemia " belongs to deficiency in origin and excess in superficiality.Deficiency in origin is meant that mainly liver,spleen,kidney three deficiency of five ZANG-organs decrease, the real turbid and congestion of expectorant that mainly refers to of mark.The rule of treatment is " blood circulation promoting and blood stasis dispelling, spleen invigorating dehumidifying, the liver and the kidney tonifying." the contained active substance flavonoid of each raw material, lovastatin have significant blood fat reducing function by a large amount of documents and clinical practice proof.According to the property of Chinese medicine, distinguish the flavor of, return through, cure mainly and compatibility, Chinese medicine Folium Ginkgo, Monas cuspurpureus Went all have the effect of blood circulation promoting and blood stasis dispelling, and Folium Ginkgo has astringing lung-QI and dissipating phlegm, Monas cuspurpureus Went invigorating the spleen and regulating the stomach concurrently, add Radix Polygoni Multiflori Preparata, Rhizoma Alismatis invigorating the liver and kidney, the effect of benefiting essence-blood finally reaches the purpose for the treatment of both the principal and secondary aspects of a disease.
The raw material that the present invention selects for use is medicine and food raw materials, and meet the requirement of the Pharmacopoeia of the People's Republic of China one one regulation in 2005 and GB etc., the scope that meets clinical taking dose and effective dose, from the consumption of effective compatibility and safety, all meet the requirement of health food or drug formulation, so this prescription is safe and effective.Health food that makes or medicine can be taken 3 every day, and each 1, eliminating cold for resuscitation water clothes down.
The functional component of health food of the present invention or medicine, accurate positioning, have give prominence to the key points, take into account in many ways, definite effect, advantage such as safe and reliable, the incomparable advantage of like product is arranged.
The specific embodiment
Below in conjunction with embodiment, the specific embodiment of the present invention is described in further detail.
Following examples are used to illustrate the present invention, but are not used for limiting the scope of the invention.
Embodiment 1: a kind of tablet formulation with auxiliary lipid-lowering function
Prescription Folium Ginkgo extract 45g, Monas cuspurpureus Went 165g, Radix Polygoni Multiflori Preparata extract 50g, Rhizoma Alismatis extract 150g
1, batching: Folium Ginkgo extract (is bought in Hanyin Heye Madison Plant Pharmaceutical Co., Ltd., total flavones 〉=5.0%), Monas cuspurpureus Went (is bought the good one-tenth biological product company limited in Wuhan, be functional Monascus, lovastatin 〉=0.5% wherein), Radix Polygoni Multiflori Preparata extract (is bought in Hanyin Heye Madison Plant Pharmaceutical Co., Ltd., general anthraquinone 〉=1.0%), Rhizoma Alismatis extract (is bought in Hanyin Heye Madison Plant Pharmaceutical Co., Ltd., alisol 〉=0.5%) pick test qualified after, remove outer package, enter clean area, standby.
2, sieve: take by weighing formula ratio Monas cuspurpureus Went, Folium Ginkgo extract, Radix Polygoni Multiflori Preparata extract, Rhizoma Alismatis extract raw material and cross 80 mesh sieves respectively, standby.
3, mix: Monas cuspurpureus Went, Folium Ginkgo extract, Radix Polygoni Multiflori Preparata extract, Rhizoma Alismatis extract are put three-dimensional wave and mix 30min in the mixer, to the color and luster uniformity, no color differnece, mixed powder, standby.
4, tabletting: adopt tablet machine to make tablet.
5, outer package is carried out in accordance with regulations sampling inspection, after the assay was approved, and the finished product warehouse-in.
Embodiment 2: a kind of capsule preparations with auxiliary lipid-lowering function
Prescription Folium Ginkgo extract 90g, Monas cuspurpureus Went 110g, Radix Polygoni Multiflori Preparata extract 100g, Rhizoma Alismatis extract 100g
1, batching: Folium Ginkgo extract (is bought in Hanyin Heye Madison Plant Pharmaceutical Co., Ltd., total flavones 〉=5.0%), Monas cuspurpureus Went (is bought the good one-tenth biological product company limited in Wuhan, lovastatin 〉=0.5%), Radix Polygoni Multiflori Preparata extract (is bought in Hanyin Heye Madison Plant Pharmaceutical Co., Ltd., general anthraquinone 〉=1.0%), Rhizoma Alismatis extract (is bought in Hanyin Heye Madison Plant Pharmaceutical Co., Ltd., alisol 〉=0.5%) pick test qualified after, remove outer package, enter clean area, standby.
2, sieve: take by weighing formula ratio Monas cuspurpureus Went, Folium Ginkgo extract, Radix Polygoni Multiflori Preparata extract, Rhizoma Alismatis extract raw material and cross 80 mesh sieves respectively, standby.
3, mix: Monas cuspurpureus Went, Folium Ginkgo extract, Radix Polygoni Multiflori Preparata extract, Rhizoma Alismatis extract are put three-dimensional wave and mix 30min in the mixer, to the color and luster uniformity, no color differnece, mixed powder, standby.
4, adorn capsule, select capsule, polishing, packing: adopt full-automatic hard capsule filler filled capsules.Adjusting and filling loading amount is the 400mg/ grain.Defect ware is removed in capsule inspection after the filling, after the polishing of reuse medicine buffing machine, in the bottled production line branch plastic bottle of packing into, 60 every bottle.
5, outer package is carried out in accordance with regulations sampling inspection, after the assay was approved, and the finished product warehouse-in.
Embodiment 3: a kind of health-caring capsule with auxiliary lipid-lowering function
Prescription Folium Ginkgo extract 135g, Monas cuspurpureus Went 55g, Radix Polygoni Multiflori Preparata extract 150g, Rhizoma Alismatis extract 50g
1, batching: Folium Ginkgo extract (is bought in Hanyin Heye Madison Plant Pharmaceutical Co., Ltd., total flavones 〉=5.0%), Monas cuspurpureus Went (is bought the good one-tenth biological product company limited in Wuhan, lovastatin 〉=0.5%), Radix Polygoni Multiflori Preparata extract (is bought in Hanyin Heye Madison Plant Pharmaceutical Co., Ltd., general anthraquinone 〉=1.0%), Rhizoma Alismatis extract (is bought in Hanyin Heye Madison Plant Pharmaceutical Co., Ltd., alisol 〉=0.5%) pick test qualified after, remove outer package, enter clean area, standby.
2, sieve: take by weighing formula ratio Monas cuspurpureus Went, Folium Ginkgo extract, Radix Polygoni Multiflori Preparata extract, Rhizoma Alismatis extract raw material and cross 80 mesh sieves respectively, standby.
3, mix: Monas cuspurpureus Went, Folium Ginkgo extract, Radix Polygoni Multiflori Preparata extract, Rhizoma Alismatis extract are put three-dimensional wave and mix 30min in the mixer, to the color and luster uniformity, no color differnece, mixed powder, standby.
4, adorn capsule, select capsule, polishing, packing: adopt full-automatic hard capsule filler filled capsules.Adjusting and filling loading amount is the 400mg/ grain.Defect ware is removed in capsule inspection after the filling, after the polishing of reuse medicine buffing machine, in the bottled production line branch plastic bottle of packing into, 60 every bottle.
5, outer package is carried out in accordance with regulations sampling inspection, after the assay was approved, and the finished product warehouse-in.
The test example:
Adopt the product (Beijing Tongrentang Health Pharmaceutical Co., Ltd. produces for the product among the embodiment 2, called after " happy power capsule ") of optimization formula preparation of the present invention to carry out toxicity and function test.
Below data by experiment illustrate effect of the present invention.
Toxicological test:
Test objective: whether the check product has toxicity.
Test material: sample: happy power capsule, human body recommended amounts are 1200mg every day.
Laboratory animal: cleaning level Kunming mouse and wistar kind rat and feedstuff.
Test method:
(irritate stomach with the per os of 0.2mL/10gbw and tried thing by acute toxicity test in mice, observe 14d), (five dosage are established in test to Salmonella reversion test, be respectively 0.004,0.02,0.1,0.5,2.5mg/ ware, establish simultaneously from beaming back change, solvent control and the contrast of positive mutagens), (3 dosage of test group are respectively 10.0g/kgbw to the PCEMNR micronucleus test, 5.0g/kgbw, 2.5g/kgbw, other establishes negative control group (deionized water) and positive controls, tried thing and negative control group and irritated stomach by the 0.2mL/10gbw per os, positive thing is pressed the 0.1mL/10gbw per os and is irritated stomach), (positive group gives the cyclophosphamide of 40mg/kgbw dosage by the 0.1mL/10gbw lumbar injection in the mouse sperm deformity test, the negative contrast of deionized water, 3 dosage of test group are respectively 10.0g/kg ' bw, 5.0g/kgbw, 2.5g/kgbw, experimental group and negative control group are pressed the 0.2mL/10gbw per os and are irritated stomach), (be divided into four groups at random by body weight is negative control group and 2g/kgbw to 30 days feeding trials, 1g/kgbw, 0.1g/kgbw three dosage groups according to dosage designed oral administration in continuous 30 days) carry out the toxicology test evaluation.
Result of the test:
1. acute oral toxicity test: female, male mice acute oral MTD is all greater than 15g/kgBW.
2. PCEMNR micronucleus test: the result is negative.
3. mouse sperm deformity test: the result is negative.
4.Ames test: the result is negative.
5.30 it feeding trial: the evaluation criterion according to 30 days feeding trials in the Ministry of Public Health " health food check with assessment technique standard " (version in 2003) is judged: in being subjected to the amount of reagent scope, happy power capsule compares etc. the weight in wet base of the every inspected biochemical indicator of the every conventional index of body weight gain, food utilization, food-intake, blood, blood of rat and internal organs and dirty/body and there is no obvious influence.Every data are learned the processing there was no significant difference by statistics.Histopathologic examination does not see that the significant histopathology relevant with being tried thing changes yet
Function test:
Test objective: whether the check product has the function of auxiliary antilipemic
Auxiliary antilipemic animal function test:
Test material: sample: happy power capsule, human body recommended amounts are 1200mg every day, i.e. 20mg/kgBW.Accurately measure and tried thing 0.2g, 1g, 6g and be settled to the 100mL mixing with deionized water respectively.
Experimental animal: cleaning level wistar kind rat 40 only reaches feedstuff, male, body weight is that 152-162g dosage selects and sample treatment: the dosage that is tried basic, normal, high three dosage groups of thing is respectively 20mg/kgbw, 100mg/kgbw, 600mg/kg ' bw (be equivalent to respectively human body recommended dose 1,5,30 times).With deionized water that diluted sample is extremely required, irritating the stomach amount is 1mL/100gbw.
Key instrument and reagent: 7600 automatic clinical chemistry analyzers.
Test method:, get tail blood and survey serum total cholesterol (TC), triglyceride (TG) and high density lipoprotein (HDL-C) by selecting 40 of healthy adult rats for use.Be divided into four groups at random according to the TC level, each group all gives high lipid food and feeds.Each dosage group is all irritated stomach by 1mL/100gbw and was tried thing 30 days.High fat matched group then gives the deionized water with volume.Fasting 16h before the off-test, broken end is got blood, measures TC, TG, three indexs of HDL-C.Carry out assessment of function.
Concrete experimental result data sees the following form:
The happy power capsule of table 1 is to the influence of rat fat index
Annotate: compare with high fat matched group: * P＜0.05:**P＜0.01.
By the listed result of table 1 as seen, TC, TG, the HDL-C value of each dosage treated animal serum there are no significant difference (P＞0.05) before the test.After the test, the TC of each test group animal serum, TG value all are lower than high fat matched group, learn check by statistics, the TC value of middle and high dosage group and the TG value of basic, normal, high dosage group and high fat matched group relatively have significant difference (P＜0.05) and highly significant (P＜0.01); The HDL-C value of the middle and high dosage group in test back is higher than high fat matched group, learns by statistics and detects, and significant difference (P＜0.05) and highly significant (P＜0.01) are arranged.
Result of the test: happy power capsule auxiliary antilipemic animal test results is positive.
The auxiliary lipid-lowering function human feeding trial:
Test objective: whether the check product has the function of auxiliary antilipemic
Test material: sample: happy power capsule No. 1, No. 2, the two is at outward appearance, taste basically identical, and one of them is happy power capsule, and another is a placebo.Human oral every day 3 times, each 1, the 0.4g/ grain.
Key instrument, reagent and test environment require: electrocardiogram, X line fluoroscopic machine, B ultrasonic scanner, biochemistry analyzer, blood counting instrument, sphygomanometer etc.
Test method: adopt two kinds of EXPERIMENTAL DESIGN of contrast between self and group.Be divided into happy power capsule test-meal group and placebo group at random by experimenter's blood lipid level, consider influence result's principal element such as age, sex, diet etc. as far as possible, carry out harmony to check, with the comparability between the assurance group.Carry out the test-meal test by double-blind method.
Concrete experimental result data sees the following form
Before and after the test-meal test change of serum C HOL, the horizontal situation of change of TG see Table 2, table 3 and table 4.Before the test, matched group and test-meal group change of serum C HOL, TG level compare, and difference does not have significance (P＞0.05), points out between two groups to have comparability.Compare before CHOL, TG and the test-meal after the test-meal of test-meal group, difference has significance (P＜0.05), and relatively, difference has significance (P＜0.05) after test-meal group test back CHOL, TG and the matched group test-meal.The HDL-C level is not seen obvious change (P＞0.05) before and after the test-meal.
Change of serum C HOL, TG, HDL-C level before the table 2 test-meal test
Change of serum C HOL, TG, HDL-C level before and after the table 3 test-meal test
Annotate: compare relatively P＜0.05 of P＜0.05# and matched group before * and the test-meal
Change of serum C HOL, TG, HDL-C situation of change before and after table 4 test-meal
Result of the test:
Adopt counter point between own control and group, the volunteer that selection meets experimental condition takes and is tried thing after 45 days, the result shows, take after the test-meal of happy power capsule test group before CHOL, the TG and test-meal relatively, difference has significance (P＜0.05), and descends 10.84%, 18.37% more respectively before CHOL, TG and the test-meal after the test-meal; Relatively, difference has significance (P＜0.05) after test-meal group test back CHOL, TG and the matched group test-meal; Test-meal group HDL-C and matched group comparing difference do not have significance (P＞0.05) after the test-meal.Do not see obvious adverse reaction during the test-meal.According to the judgment criteria of regulation in " health food check and assessment technique standard " (version in 2003), the happy power capsule of prompting given the test agent has the auxiliary lipid-lowering function effect.
The above only is a preferred implementation of the present invention; should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the technology of the present invention principle; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (10)
1. the compositions with auxiliary lipid-lowering function is characterized in that, is mainly made by the material of following parts by weight: Folium Ginkgo extract: 4.5-13.5 part; Monas cuspurpureus Went: 5.5-16.5 part; Radix Polygoni Multiflori Preparata extract: 5-15 part; Rhizoma Alismatis extract 5-15 part.
2. compositions as claimed in claim 1 is characterized in that, is mainly made by the material of following parts by weight: Folium Ginkgo extract: 9 parts; Monas cuspurpureus Went: 11 parts; Radix Polygoni Multiflori Preparata extract: 10 parts; Rhizoma Alismatis extract: 10 parts.
3. compositions as claimed in claim 1 or 2 is characterized in that, described Folium Ginkgo extract contains total flavones 〉=5.0 weight %.
4. compositions as claimed in claim 1 or 2 is characterized in that, described Monas cuspurpureus Went contains lovastatin 〉=0.5 weight %.
5. compositions as claimed in claim 1 or 2 is characterized in that, described Radix Polygoni Multiflori Preparata extract contains general anthraquinone 〉=1.0 weight %.
6. compositions as claimed in claim 1 or 2 is characterized in that, described Rhizoma Alismatis extract contains alisol 〉=0.5 weight %.
7. the health food with auxiliary lipid-lowering function is characterized in that, it contains each described compositions of claim 1-6.
8. the pharmaceutical preparation with auxiliary lipid-lowering function is characterized in that, it contains each described compositions of claim 1-6 and pharmaceutically acceptable carrier.
9. pharmaceutical preparation as claimed in claim 8 is characterized in that, described preparation is acceptable tablet, pill, capsule, granule, electuary, oral liquid or syrup clinically.
10. pharmaceutical preparation as claimed in claim 9 is characterized in that, described preparation is a capsule, and its every 100g product contains total flavones 1.3g, lovastatin 0.12g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102363225A CN101850039B (en) | 2009-10-16 | 2009-10-16 | Composition with auxiliary lipid-lowering function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102363225A CN101850039B (en) | 2009-10-16 | 2009-10-16 | Composition with auxiliary lipid-lowering function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101850039A true CN101850039A (en) | 2010-10-06 |
| CN101850039B CN101850039B (en) | 2012-06-27 |
Family
ID=42801829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102363225A Active CN101850039B (en) | 2009-10-16 | 2009-10-16 | Composition with auxiliary lipid-lowering function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101850039B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488189A (en) * | 2011-11-11 | 2012-06-13 | 北京燕京中发生物技术有限公司 | Capsule with health-care function of assisting blood lipid reduction and preparation method thereof |
| CN103251043A (en) * | 2012-03-23 | 2013-08-21 | 山东德圣医药科技有限公司 | Auxiliary hypolipidemic health-care food |
| CN103372114A (en) * | 2012-04-20 | 2013-10-30 | 北京北大维信生物科技有限公司 | Red rice and rhizoma alismatis medicinal composition for regulating blood fat and preparation method of composition |
| CN107173806A (en) * | 2017-06-09 | 2017-09-19 | 耿成好 | A kind of health food and preparation method with blood fat reducing function |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100336517C (en) * | 2005-07-29 | 2007-09-12 | 南京海陵中药制药工艺技术研究有限公司 | Red rice and gingko leaf composition for preventing and treating cardiovascular and cerebrovascular disease and its application |
| CN1850130A (en) * | 2006-02-21 | 2006-10-25 | 郭凌云 | Preparation for preventing and treating cardiovascular and cerebrovascular diseases |
| CN100493518C (en) * | 2006-05-18 | 2009-06-03 | 武汉理工大学 | A blood fat-decreasing traditional Chinese medicine and preparation method thereof |
-
2009
- 2009-10-16 CN CN2009102363225A patent/CN101850039B/en active Active
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488189A (en) * | 2011-11-11 | 2012-06-13 | 北京燕京中发生物技术有限公司 | Capsule with health-care function of assisting blood lipid reduction and preparation method thereof |
| CN102488189B (en) * | 2011-11-11 | 2013-04-24 | 北京燕京中发生物技术有限公司 | Capsule with health-care function of assisting blood lipid reduction and preparation method thereof |
| CN103251043A (en) * | 2012-03-23 | 2013-08-21 | 山东德圣医药科技有限公司 | Auxiliary hypolipidemic health-care food |
| CN103372114A (en) * | 2012-04-20 | 2013-10-30 | 北京北大维信生物科技有限公司 | Red rice and rhizoma alismatis medicinal composition for regulating blood fat and preparation method of composition |
| CN103372114B (en) * | 2012-04-20 | 2015-01-21 | 北京北大维信生物科技有限公司 | Red rice and rhizoma alismatis medicinal composition for regulating blood fat and preparation method of composition |
| CN107173806A (en) * | 2017-06-09 | 2017-09-19 | 耿成好 | A kind of health food and preparation method with blood fat reducing function |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101850039B (en) | 2012-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6873517B2 (en) | Health-maintaining product composition applicable to adult women, the elderly and people in sub-health conditions | |
| CN101912015B (en) | Formula of Chinese medicinal life-nourishing tea bag and preparation method thereof | |
| CN104688791B (en) | The composition for the saponin improved with bioavilability | |
| CN104784505B (en) | A kind of Dendrobium officinale health product of auxiliary hyperglycemic and preparation method thereof | |
| CN102488189B (en) | Capsule with health-care function of assisting blood lipid reduction and preparation method thereof | |
| CN107518260A (en) | A kind of food and preparation method thereof | |
| KR101906720B1 (en) | Composition comprising the combination extract of Lycium chinensis, Glycyrrhiza urlaensis FISCH, Foeniculum vulagare MILL, Glycine max MERR, and Pueraria thunbergiana BENTH for preventing and treating menopause-related disease and depression | |
| CN101850039B (en) | Composition with auxiliary lipid-lowering function | |
| CN102697843B (en) | Health care product for cleaning colon and promoting defecation, and eliminating toxin and beautifying skin and preparation method of same | |
| CN106666703A (en) | Enzyme composition with liver-protecting function, as well as preparation and preparation method thereof | |
| CN108850354A (en) | A kind of anti-aging return of spring tea-drinking dissipates and preparation method thereof | |
| CN105533749B (en) | It is a kind of containing Herba Epimedii, the health food of Schisandra chinensis and its preparation method and application | |
| CN105853505A (en) | Qi-and-lung-tonifying healthcare medicine composition containing five-leaf gynostemma herb | |
| CN108471795A (en) | The food compositions for preventing and alleviating female menopausal symptoms containing grape seed extract, Valerian root P.E and safflower seed extract | |
| CN111480846A (en) | Health-care product for assisting in reducing blood fat and improving immunity | |
| CN105726921A (en) | Traditional Chinese medicine composition and preparation for treating deficiency of both qi and blood | |
| KR101668447B1 (en) | Composition for curing hanover and health functional foods composition comprising the same | |
| CN113016969A (en) | Yin deficiency constitution health-care solid beverage and preparation method thereof | |
| CN110301639A (en) | Drug extract, rhizoma polygonati compound oral liquid and preparation method with its preparation | |
| KR102588771B1 (en) | COMPOSITION COMPRISING EXTRACT Colpomenia sinuosa OR Colpomenia peregrina Sauvageau AS AN ACTIVE INGREDIENT FOR ALLEVIATING OR IMPROVING SYMPTOM BY ESTROGEN REDUCING | |
| CN103520401B (en) | A kind of Traditional Chinese medicine health-preserving preparation with auxiliary lipid-lowering function | |
| KR101370577B1 (en) | A beverage composition using sponges and cabbage and its manufacturing method | |
| CN114246337B (en) | Composition for strengthening spleen, eliminating dampness and losing weight as well as preparation method and application thereof | |
| KR102347819B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
| KR100553307B1 (en) | A functional red ginseng drink comprising extract of Korean mistletoe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |